FDA approves Roche ’s Hemlibra (emicizumab-kxwh) for haemophilia A with inhibitors
Roche today announced that the US Food and Drug Administration (FDA) has approved Hemlibra ® (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Bleeding | Children | Food and Drug Administration (FDA) | Haemophilia | Hemophilia | Pharmaceuticals